Long Non-Coding RNA UBA6-AS1 Promotes the Malignant Properties of Glioblastoma by Competitively Binding to microRNA-760 and Enhancing Homeobox A2 Expression

Cheng, Feifei; Liu, Jiang; Zhang, Yundong; You, Qi; Chen, Bin; Cheng, Jing; Deng, Chunyan

doi:10.2147/cmar.s287676

Cited by 7 publications

(4 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…has been shown to be a highly reliable predictor of clinical prognosis in patien ts with hepatocellular carcinoma and colorectal cancer (10,11), while SUCLG2-AS is a promising biomarker for predicting prognostic risk in triple-negative br east cancer and clear cell renal cell carcinoma (12,13). UBA6-AS1 not only in hibits the malignancy of ovarian cancer cells by suppressing the decay of UBA 6 mRNA ( 14) but has also been shown to promote malignant progression of G BM by targeting miR-760 and enhancing homeobox A2 expression (15). Moreov er, ZBTB20-AS4 has also been found to be associated with overall survival in glioma (16,17).…”

Section: Discussionmentioning

confidence: 99%

Identification of a Novel Disulfideptosis-Related LncRNA Signature and Integrative Analyses in Patients with Gliomas

Cao,

Li,

Liu

et al. 2023

Preprint

View full text Add to dashboard Cite

Glioma, a prevalent type of brain cancer, is associated with poor prognosis. The purpose of this study was to investigate the correlation between disulfidptosis-related lncRNAs (DRLncs) and survival outcomes of glioma patients. Transcriptome and clinical data for glioma patients were retrieved from The Cancer Genome Atlas (TCGA) database. Ten disulfidptosis-related genes (DRGs) were identified from literature. Co-expression analysis was performed to identify DRLncs associated with glioma. A risk prognostic model for DRLncs was constructed using COX regression analysis and LASSO regression analysis. The model was validated by dividing samples evenly into training and test groups and conducting various analyses including survival analysis, ROC curve analysis, independent prognostic analyses, and PCA. GO and KEGG enrichment analysis was also performed on differentially expressed genes between high-risk and low-risk groups. Variances in the immune microenvironment, immune cells, and immune-related functions were analyzed between high-risk and low-risk groups. Drug sensitivity analysis was conducted to identify potential therapeutic drugs for glioma treatment, and the TIDE database was used to evaluate the potential for immune escape. The expression of DRLncs in glioma was verified through real-time quantitative PCR. Through co-expression analysis, 136 disulfidptosis-related LncRNAs were identified. Univariate Cox analysis revealed that 86 of these LncRNAs significantly correlated with overall survival (OS) in glioma patients. Using the Lasso-Cox method, a model consisting of 7 LncRNAs was constructed and optimized. This model effectively differentiated between individuals at high risk and those at low risk, with good survival prediction ability. GO and KEGG analysis indicated that the differential gene enrichment in the high- and low-risk groups was related to immune-related functions. The study observed divergences in the immune microenvironment, immune cells, and immune-related functions between the high-risk and low-risk groups. Furthermore, immunotherapy response scoring indicated that patients in the low-risk group exhibited better response to immunotherapy. Finally, real-time quantitative PCR results showed that the expression of low-risk LncRNA (ZBTB20-AS4) was low in tumor tissue, while the expression of high-risk LncRNAs (POLR2J4, SUCLG2-AS1, and UBA6-AS1) was high in glioma tumor tissue. Overall, this study established a novel glioma prognosis model that explored disulfidptosis-related lncRNAs to guide glioma prognosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Identification of a Novel Disulfideptosis-Related LncRNA Signature and Integrative Analyses in Patients with Gliomas

Cao,

Li,

Liu

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…In this model, several sIRlncRs had been found to play an important role in the malignant phenotypes of various cancer types, such as AC022509.2, 30 LINC02544, 33 AC091057.1, 34 HLA-DQB1-AS1, 34 SEMA6A-AS1, 35 AL365361.1, 36 , 37 and UBA6-AS1. 38 For example, UBA6-AS1 promoted GBM’s malignant progression by targeting the miR-760/HOXA2 axis. Therefore, this model could be used to identify novel biomarkers.…”

Section: Discussionmentioning

confidence: 99%

Identification and Validation of Immune-Related lncRNA Signature as a Prognostic Model for Skin Cutaneous Melanoma

Shuai¹,

Wang²,

He³

et al. 2021

PGPM

View full text Add to dashboard Cite

Purpose Skin cutaneous melanoma (SKCM) is the most aggressive skin cancer that results in high morbidity and mortality rate worldwide. Immune-related long non-coding RNAs (IRlncRs) play an important role in regulating gene expression in tumors. Therefore, in this study, we aimed to identify IRlncRs signature that could predict prognosis and therapeutic targets for melanoma irrespective of the gene expression levels. Methods RNA-sequencing data were obtained from The Cancer Genome Atlas (TCGA). IRlncRs were identified using co-expression analysis and recognized using univariate analysis. The impact of IRlncRs on survival was analyzed using a modified least absolute shrinkage and selection operator (Lasso) regression model. A 1-year survival receiver operating characteristic curve was constructed, and the area under the curve was calculated to identify the optimal cut-off point to distinguish between high and low-risk groups in patients with SKCM. Furthermore, integrative analysis was performed to identify the impact of clinicopathological features, chemotherapeutic treatment, tumor-infiltrating immune cells, and mutant genes on survival. Results A total of 28 IRlncRs significantly associated with survival were identified. Seventeen IRlncRs pairs were used to build a survival risk model that could be used to distinguish between low and high-risk groups. The high-risk group was negatively associated with tumor-infiltrating immune cells and had a higher half inhibitory centration for chemotherapeutic agents such as cisplatin and vinblastine. Additionally, the high-risk group had a positive correlation with the expression of specific mutant genes such as BRAF and KIT. Conclusion Our findings demonstrate that some IRlncRs have a significant correlation with survival and therapeutic targets for SKCM patients and may provide new insight into the clinical diagnosis and treatment strategies for SKCM patients.

show abstract

“…LncRNA UBA6-AS1 expression was enhanced in glioblastoma. Through miR-760/HOXA2 regulation, UBA6-AS1 inhibition can improve apoptosis ( Cheng et al, 2021 ). LncRNA KCNQ1OT1 significantly was Up-Regulated in glioma.…”

Section: Non-coding Rnas and Brain Tumorsmentioning

confidence: 99%

Non-Coding RNAs and Brain Tumors: Insights Into Their Roles in Apoptosis

Tamtaji

Derakhshan

Noshabad

et al. 2022

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

A major terrifying ailment afflicting the humans throughout the world is brain tumor, which causes a lot of mortality among pediatric and adult solid tumors. Several major barriers to the treatment and diagnosis of the brain tumors are the specific micro-environmental and cell-intrinsic features of neural tissues. Absence of the nutrients and hypoxia trigger the cells’ mortality in the core of the tumors of humans’ brains: however, type of the cells’ mortality, including apoptosis or necrosis, has been not found obviously. Current studies have emphasized the non-coding RNAs (ncRNAs) since their crucial impacts on carcinogenesis have been discovered. Several investigations suggest the essential contribution of such molecules in the development of brain tumors and the respective roles in apoptosis. Herein, we summarize the apoptosis-related non-coding RNAs in brain tumors.

show abstract

Long Non-Coding RNA UBA6-AS1 Promotes the Malignant Properties of Glioblastoma by Competitively Binding to microRNA-760 and Enhancing Homeobox A2 Expression

Cited by 7 publications

References 37 publications

Identification of a Novel Disulfideptosis-Related LncRNA Signature and Integrative Analyses in Patients with Gliomas

Identification of a Novel Disulfideptosis-Related LncRNA Signature and Integrative Analyses in Patients with Gliomas

Identification and Validation of Immune-Related lncRNA Signature as a Prognostic Model for Skin Cutaneous Melanoma

Non-Coding RNAs and Brain Tumors: Insights Into Their Roles in Apoptosis

Contact Info

Product

Resources

About